Invention Grant
- Patent Title: Phosphopeptides as melanoma vaccines
- Patent Title (中): 磷酸肽作为黑素瘤疫苗
-
Application No.: US13318821Application Date: 2010-05-04
-
Publication No.: US09279011B2Publication Date: 2016-03-08
- Inventor: Suzanne L. Topalian , Florence A Depontieu , Donald F. Hunt , Jeffrey Shabanowitz , Jie Qian , Victor H. Engelhard , Angela Lee Zarling
- Applicant: Suzanne L. Topalian , Florence A Depontieu , Donald F. Hunt , Jeffrey Shabanowitz , Jie Qian , Victor H. Engelhard , Angela Lee Zarling
- Applicant Address: US MD Baltimore US VA Charlottesville
- Assignee: The Johns Hopkins University,University of Virginia Patent Foundation
- Current Assignee: The Johns Hopkins University,University of Virginia Patent Foundation
- Current Assignee Address: US MD Baltimore US VA Charlottesville
- Agency: Banner & Witcoff, LTD.
- International Application: PCT/US2010/033530 WO 20100504
- International Announcement: WO2010/129537 WO 20101111
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K47/00 ; C07K14/47 ; G01N33/574 ; C12Q1/68 ; A61K39/39

Abstract:
We characterized a total of 175 HLA-DR-associated phosphopeptides using sequential affinity isolation, biochemical enrichment, mass spectrometric sequencing and comparative analysis. Many were derived from source proteins which may have roles in cancer development, growth and metastasis. Most were expressed exclusively by either melanomas or transformed B cells, suggesting the potential to define cell type-specific phosphatome “fingerprints”. We generated HLA-DRβ1*0101-restricted CD4+ T cells specific for a phospho-MART-1 peptide identified in two melanoma cell lines. These T cells showed specificity for phosphopeptide-pulsed antigen presenting cells as well as for intact melanoma cells. MHC II-restricted phosphopeptides recognizable by human CD4+ T cells are potential targets for cancer immunotherapy.
Public/Granted literature
- US20120177669A1 PHOSPHOPEPTIDES AS MELANOMA VACCINES Public/Granted day:2012-07-12
Information query